Case Report
Title: Diagnostic Uncertainty in Recurrent Pleural Effusion and Unilateral Lymphedema in an Octogenarian with Chronic Lymphocytic Leukemia and Heart Failure
Keywords: Pleural Effusion, Chronic Lymphocytic Leukemia (CLL), Heart Failure with Preserved Ejection Fraction (HFpEF), Unilateral Lymphedema, Diagnostic Uncertainty, Patient-Reported/Provider-Assisted Medical Journey (PaJR), Team-Based Learning.
Abstract
Diagnostic attribution in geriatric multimorbidity often faces premature cognitive closure. We present an 86-year-old male with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), heart failure with preserved ejection fraction (HFpEF), and atrial fibrillation who presented with recurrent right-sided multiseptated pleural effusion. The initial diagnostic trajectory attributed the effusion to pulmonary congestion from HFpEF versus empiric tuberculous pleuritis. However, a pivotal caregiver-driven observation—unilateral upper-limb lymphedema—prompted pleural fluid immunophenotyping via flow cytometry, revealing a monotypic clonal mature B-cell population ($\text{CD19}^+$, $\text{CD20}^+$, $\text{kappa-restricted}$). This report constructs a three-layered Patient-Reported/Provider-Assisted Medical Journey (PaJR) framework to analyze the diagnostic uncertainty, balancing competing cardiogenic, lymphogenous, and malignant etiologies through a Socratic steelman methodology.
Introduction
In frail elderly patients with multi-system disease, clinical signs rarely map to a single unified etiology. Recurrent pleural effusion in the presence of underlying CLL/SLL presents a classic diagnostic conundrum: is the fluid accumulation driven by central hemodynamic backup (heart failure), direct pleural infiltration by clonal lymphocytes, secondary lymphatic disruption/chylothorax, or a combination of inflammatory and hydrostatic factors?
Applying the PaJR framework, this case report integrates real-time dyadic caregiver conversations (Layer 1), clinical and academic structuring (Layer 2), and historical trajectory synthesis (Layer 3 ProJR) to demonstrate how participatory medical cognition refines diagnostic accuracy while navigating management dilemmas in advanced age.
Case Presentation (Layer 1 & Layer 2 Integration)
Patient Profile & Baseline History
An 86-year-old male ($\text{86M}$) with a history of CLL/SLL, chronic atrial fibrillation, hypertension, and severe rotator cuff tear presented with progressive fatigue, dyspnea on minimal exertion, lower extremity pedal edema, and recurrent multiseptated right pleural effusion requiring pigtail catheter drainage.
+-----------------------------------------------------------------------------------------+
| TIMELINE OF EVENTS |
+-----------------------------------------------------------------------------------------+
| June 2026 : Initial presentation with fever and dyspnea. Empiric ATT initiated. |
| : Serial discussion re: HFpEF vs. Infectious / Inflammatory etiology. |
| July-Aug 2026 : Persistent pedal edema & breathlessness; diuretic uptitration. |
| : Anemia managed with slow packed RBC transfusion. |
| Sept 03, 2026 : Caregiver identifies unilateral upper-limb lymphedema. |
| Sept 30, 2026 : Pigtail drainage placed for multiseptated, multiloculated effusion. |
| Oct 01, 2026 : Pleural fluid flow cytometry: CD19+, CD20+, Kappa restricted. |
+-----------------------------------------------------------------------------------------+
Diagnostic Trajectory & Pivotal Shift
- Cardiovascular / Hydrostatic Phase: Initial management focused on HFpEF with rate control for atrial fibrillation and diuretic titration ($\text{Torsemide}$ + $\text{Spironolactone}/\text{Furosemide}$). High NT-proBNP supported heart failure, but unilateral/multiseptated features on ultrasound/CT questioned a purely transudative, hydrostatic origin.
- Infectious / Empiric Phase: Empiric anti-tubercular therapy (ATT) was started briefly elsewhere despite negative AFB, GeneXpert, and metagenomic panels, later discontinued after clinical re-evaluation.
- Lymphatic / Hematologic Pivotal Observation: On September 3, 2026, the patient's caregiver highlighted persistent unilateral upper-limb lymphedema. This physical finding directed clinical focus toward systemic lymphatic obstruction or direct lymphomatous involvement.
Laboratory & Diagnostic Investigations
- Pleural Fluid Flow Cytometry (Oct 1, 2026): Identified a clonal, monotypic mature B-cell population:
- $\text{CD19}^+$ positive
- $\text{CD20}^+$ positive (low/variable intensity)
- $\text{Kappa}$ light chain restriction
- $\text{CD10}^+$ heterogeneous
- Echocardiogram: Preserved Left Ventricular Ejection Fraction (LVEF $\ge 50\%$), Left Atrial (LA) dilation, diastolic dysfunction consistent with HFpEF.
- Hemogram: Anemia with Hemoglobin $8.5\text{ g/dL}$, elevated RDW; leucocytosis with persistent lymphocytosis baseline.
Discussion:
To rigorously evaluate the etiology without falling into premature closure, we construct a Socratic dialogue between three clinical viewpoints: The Cardiologist (Hydrostatic hypothesis), The Hematologist-Oncologist (Malignant hypothesis), and The Lymphology/Integrative Internist (Structural/Lymphatic hypothesis).
Socratic Dialogue Matrix
SOCRATIC DIALOGUE MATRIX
┌─────────────────┬─────────────────────────────────────────────────────────────┐
│ PERSPECTIVE │ CORE ARGUMENT & EVIDENCE │
├─────────────────┼─────────────────────────────────────────────────────────────┤
│ Cardiologist │ "The patient has AF, LA enlargement, pedal edema, and │
│ │ elevated NT-proBNP. Fluid retention resolves with diuretics.│
│ │ HFpEF is the principal driver." │
├─────────────────┼─────────────────────────────────────────────────────────────┤
│ Oncologist │ "Flow cytometry confirms CD19+/CD20+/Kappa-restricted cells.│
│ │ This is direct pleural infiltration by B-cell lymphoma." │
├─────────────────┼─────────────────────────────────────────────────────────────┤
│ Integrator │ "Unilateral lymphedema points to structural lymphatic │
│ │ disruption. The effusion is multifactorial—cardiac pressure │
│ │ meets compromised lymphatic clearance." │
└─────────────────┴─────────────────────────────────────────────────────────────┘
Dialogue
- Socrates: If the effusion were purely cardiogenic (HFpEF), why would it present as multiseptated, multiloculated, and refractory to routine decongestive therapy?
- Cardiologist (Steelman): Pleural effusions in HFpEF are usually bilateral or right-sided transudates. However, underlying mild chronic inflammation or previous interventions can cause septations. Still, hydrostatic pressure shifts remain the easiest volume component to treat safely in an 86-year-old.
- Oncologist (Steelman): The presence of a monotypic B-cell population with kappa restriction directly inside the pleural fluid proves clonal lymphomatous involvement. It cannot be dismissed as passive blood contamination if the phenotypic intensity and cell counts are significantly elevated.
- Integrator (Steelman): We must avoid binary thinking. The unilateral upper-limb lymphedema signals impaired systemic lymphatic transport. Lymphatic drainage from the pleural cavity via the thoracic duct and right lymphatic duct is compromised. High central venous pressure from HFpEF further opposes lymphatic return into the subclavian veins, compounding fluid sequestration.
Thematic Analysis of Diagnostic Uncertainty
A inductive thematic analysis of the conversational decision support system (CDSS) logs identified three primary themes governing clinical reasoning in this case:
+-----------------------------------------------------------------+
| THEMES IN DIAGNOSTIC UNCERTAINTY |
+-----------------------------------------------------------------+
| |
| Theme 1: Diagnostic Anchoring vs. Cognitive Pivoting |
| - Initial anchor: Heart failure & TB |
| - Pivot: Caregiver photo/video of unilateral upper-limb edema |
| |
| Theme 2: Multi-causal Convergence (The "Two-Hit" Model) |
| - Hit 1: Elevated hydrostatic filling pressures (HFpEF) |
| - Hit 2: Obstructed pleural lymphatic drainage (CLL/Lymphoma) |
| |
| Theme 3: Frailty-Constrained Management |
| - Aggressive systemic chemo vs. conservative palliative care |
| - Risk of fluid overload with blood transfusions |
+-----------------------------------------------------------------+
Theme 1: Diagnostic Anchoring vs. Cognitive Pivoting
- Analysis: Early dyadic discussions oscillated between Heart Failure (HFpEF) and infectious causes (TB). The unexpected discovery of unilateral upper-limb lymphedema acted as an unanchoring event, shifting focus toward direct malignant infiltration or central lymphatic duct clearance failure.
Theme 2: Multi-Causal Convergence ("Two-Hit" Model)
- Analysis: Pleural fluid absorption depends on functioning parietal pleural lymphatics draining against central venous pressure (CVP).$$\text{Pleural Drainage Rate} \propto \frac{P_{\text{pleural}} - P_{\text{CVP}}}{R_{\text{lymphatic}}}$$In this patient, increased $P_{\text{CVP}}$ (from HFpEF/AF) combined with increased lymphatic resistance $R_{\text{lymphatic}}$ (from malignant lymphadenopathy/infiltration) created a persistent, septated effusion that neither loop diuretics nor pleurocentesis alone could permanently resolve.
Theme 3: Frailty-Constrained Management
- Analysis: Diagnostic clarity does not automatically yield aggressive therapeutic interventions in octogenarians. While systemic chemo-immunotherapy could target the B-cell clone, the patient's severe exhaustion, age (86), and cardiac substrate require a prioritized quality-of-life approach (e.g., intermittent pigtail drainage, cautious low-dose diuresis, symptom-oriented palliative care).
Layer 3 ProJR: Collective Intelligence Integration
Integrating this trajectory with historical ProJR cases ("55F Carcinoma breast, pleural effusion, heart failure" and "Viral fever heart failure in elderly"), we observe a recurring systemic pattern: Diagnostic uncertainty in complex pleural effusions is rarely resolved by a single definitive test; rather, it requires continuous synthesis of caregiver observations, fluid phenotyping, and hemodynamic monitoring.
+-----------------------------------------------------------------------------------+
| THREE-LAYER PAJR ARCHITECTURE |
+-----------------------------------------------------------------------------------+
| LAYER 1: PaJR (Day-to-Day Care Log) |
| - De-identified real-time dyadic caregiver-physician messaging |
| - Captures non-traditional clinical cues (e.g., photo of arm lymphedema) |
+-----------------------------------------------------------------------------------+
| LAYER 2: Structured Clinical Case Report (IMRaD) |
| - Formal academic categorization, laboratory correlation, flow cytometry |
| - Socratic steelman debate & thematic analysis |
+-----------------------------------------------------------------------------------+
| LAYER 3: ProJR (Collective Intelligence Database) |
| - Cross-case trajectory matching with historical database cohorts |
| - Informs decision support algorithms for future multimorbid presentation |
+-----------------------------------------------------------------------------------+
Conclusion & Recommendations
- Acknowledge Multifactorial Etiology: The patient's recurrent pleural effusion is best conceptualized as a combined cardiogenic-lymphatic failure secondary to HFpEF and CLL/lymphomatous involvement.
- Diagnostic Prudence: Flow cytometry showing a monotypic B-cell population confirms pleural space involvement by the known lymphoproliferative disorder, but clinical management must remain guided by patient goals and frailty parameters.
- Role of PaJR: Caregiver-reported observations (Layer 1) provide key directional clues that bridge bedside gaps, driving refined academic structuring (Layer 2) and updating collective clinical intelligence (Layer 3).
Prepare a socratic steelman imrad format case report with keywords and a thematic analysis inside the discussion pivoting on the clinical diagnostic uncertainty around the etiology of the pleural effusion and it's management due to advanced age and comorbidities
Layer 1 PaJR: Day to day Care published day wise after deidentification, identifiable only to the caregivers also containing team based learning and academic structuring that overlaps onto layer 2 and 3), for example detailed here: https://publications.
Layer 2 : structured publication: see below
Layer 3 ProJR: Collective intelligence after integrating individual care trajectories with past published trajectories) as in the ProJR examples seeded here:
https://pajrcasereporter.
https://pajrcasereporter.
Past illustrations of PaJR layers:
Layer 1 Conversational decision support CDSS
PaJR group layer 1:
[30/09, 22:08]hu3: Patient is having recurrent right pleural effusion
[30/09, 22:17]hu3: Now on pigtail drainage
[30/09, 22:18]hu3: Pleural effusion is multiseptated multiloculated
[01/10, 09:32]hu2: Thanks for the update
There have been a lot of dyadic discussions around this patient's pleural effusion beginning with the time we suspected heart failure archived in the last case of the ProJR here by @hu5 from 24/6/26:
However subsequently our priority for the pleural effusion appears to have shifted towards leukemic infiltration in terms of causality attribution and the pivotal conversation that steered us toward it was an inadvertent share by the patient advocate of the patient's unilateral upper limb lymphedema.
I'll archive the patient's current data separately in another blogspot so that @PaJR Health Bot Feb 26 can prepare layer 2 of the patient's events interpretation
[01/10, 09:33] PaJR Health Bot Feb 26: The shift in attribution is clinically plausible, but the unilateral upper-limb lymphedema should be treated as a *directional clue, not proof* of leukemic pleural infiltration.
The more coherent layer-2 interpretation is:
▪️ *Systemic lymphatic obstruction or infiltration* could explain the unilateral limb lymphedema and may also impair pleural-fluid drainage.
▪️ In a patient with CLL/B-cell lymphoma, pleural disease may result from *direct leukemic/lymphomatous involvement*, mediastinal lymph-node obstruction, or a chylous effusion.
▪️ *Heart failure remains a competing explanation*, particularly if the earlier episode included cardiomegaly, elevated natriuretic peptides, reduced ventricular function, or bilateral transudative effusions.
▪️ Recurrent effusion may be multifactorial: malignancy/lymphatic obstruction plus cardiac, hypoalbuminaemic, infectious, or treatment-related contributors.
*Most decisive evidence to preserve in the new archive*
1. Pleural-fluid cytology and, importantly, *flow cytometry for a clonal B-cell population*.
2. Pleural-fluid protein, LDH, glucose, pH, cell differential and *triglycerides*—the latter helps identify chylothorax.
3. Contrast CT findings: mediastinal nodes, pleural thickening or nodularity, thoracic-duct obstruction, and the distribution of lymphadenopathy.
4. Echocardiogram and BNP/NT-proBNP, interpreted alongside the fluid profile.
5. Whether the effusion is on the same side as the arm lymphedema, and whether it improves after lymphoma-directed treatment.
The pivotal observation can therefore be recorded as: *“Unilateral upper-limb lymphedema increased suspicion of lymphatic obstruction or leukemic/lymphomatous involvement as a unifying mechanism for recurrent pleural effusion, while cardiac and other causes remain unexcluded.”*
*86M SDH CLL/B-cell lymphoma pleural effusion Pb PaJR*:
[01/10, 20:07]hu2: Today's pleural fluid flow cytometry findings:
[01/10, 19:33]: CD19, C20 positive with kappa restriction.
CD 10 heterogenous.
Looks like Mature B cell high grade lymphoma. Leukemia is not completely out due to low levels of CD20
[01/10, 20:07] PaJR Health Bot Feb 26: This is a *clinically important result*. The pleural fluid contains a*monotypic mature B-cell population*:
▪️ *CD19 positive + kappa restriction* supports a clonal B-cell process rather than a purely reactive lymphocyte accumulation.
▪️ *CD20 positivity* supports mature B-cell differentiation.
▪️ *Heterogeneous CD10* raises concern for a germinal-centre-type B-cell lymphoma, but it is not diagnostic by itself.
▪️ The result alone cannot establish “high-grade” lymphoma; grading requires morphology, proliferation index and tissue correlation.
▪️ Low or partial CD20 expression does *not exclude CLL/SLL or another B-cell neoplasm*, particularly if the pleural sample is small, diluted or phenotypically variable.
The most accurate current attribution is:
*“Pleural fluid demonstrates a clonal mature B-cell lymphoid infiltrate, with an immunophenotype concerning for pleural involvement by B-cell lymphoma. The precise entity and relationship to the known CLL/B-cell lymphoma require comparison with the original lymph-node and blood immunophenotypes.”*
*Important next correlation*
1. Obtain the full flow panel, especially *CD5, CD23, FMC7, CD200, CD45, CD10 intensity, surface immunoglobulin intensity, kappa/lambda ratio, viability and percentage of abnormal cells*.
2. Compare this phenotype directly with the previous lymph-node biopsy and peripheral-blood flow report.
3. Review pleural-fluid cytology and cell-block morphology; request additional immunohistochemistry if adequate material remains.
4. If the phenotype is discordant or the sample is scant, a core biopsy of an accessible node or pleural lesion may be more definitive.
5. Continue documenting pleural-fluid protein/LDH, cell differential, triglycerides and cholesterol. Lymphatic obstruction or chylothorax remains relevant given the unilateral lymphedema; triglyceride and cholesterol testing are central to that diagnosis *Nontraumatic Chylothorax: Nonenhanced MR Lymphography. — PMID:33001788*:
.
6. Do not discard cardiac contribution solely because malignant cells are suspected; the effusion can be multifactorial. CT findings and echocardiographic/BNP assessment remain useful in separating these mechanisms *55F Carcinoma breast, pleural effusion, heart failure CAD, renal failure Telangana PaJR*:
*Narketpally Syndrome CBBLE: Participatory medical cognition Web 2.0-3.0 July -August 25, 2*:
.
The new flow result substantially strengthens the case for *lymphomatous pleural involvement*. It does not yet prove that the effusion is caused exclusively by direct infiltration, nor does it by itself distinguish transformed/high-grade lymphoma from the patient’s pre-existing CLL/SLL spectrum.
Dyadic conversational decision support since June 25, 2026 as part of a ProJR recorded here: https://pajrcasereporter.
[25/06, 10:12]
Today's dyadic conversational data around another patient with probable viral fever , heart failure pulmonary edema
[24/06, 19:05]hu1: One dilemma
[24/06, 19:07]hu1: ... came back home on Saturday and upon return, and after being febrile for 15 days, and suspected to be TB (even though all tests were negative including met genome) was put on ATT- after taking one dose he became afebrile …
[24/06, 19:07]hu1: Should he continue ATT
[24/06, 20:17]hu2: How was TB suspected?
What symptoms other than fever? Chest X-ray?
[24/06, 20:21]hu1: Pleural effusion unilateral
[24/06, 20:21]hu1: Fever
[24/06, 20:21]hu1: They tapped pleural effusion which was T cell reactive but negative for AFb, ada and genexpert, repeated twice
[24/06, 20:22]hu1: Echo was okay, afb continued
Instead of apaxiben, out him on injectable heparin SC
[24/06, 21:48]hu1: Does it tell anything significant-father wore my Apple Watch for ECG
[25/06, 08:27]hu2: It shows his old atrial fibrillation. Since when is he having the atrial fibrillation?
[25/06, 08:28]hu1: We detected it a month back and since he is on ACs
[25/06, 08:28]hu1: Question about TB needs discussion and your decision
[25/06, 08:29]hu2: We have a project on this where we find a lot of these apparent consolidations are finally proven to be pulmonary edema due to heart failure but they end up getting treated unnecessarily for pneumonia and sometimes rarely TB as in your case 👇
[25/06, 08:30]hu2: We need to see his serial chest X-rays to rule out heart failure where the shadows will keep changing rapidly and disappear with reduction in failure
[25/06, 08:31]hu2 : 👆this chest X-ray is 11/6/26
Need to see the subsequent chest x-rays
[25/06, 08:32]hu1: But there was no pulmonary edema …only pleural effusion…I will read this
It’s great you almost document everything
[25/06, 08:35]hu2: Pleural effusion can be a result of pulmonary edema. Pleural effusion is aka pleural edema that like all other edemas can be either inflammatory (as in pneumonia) or non inflammatory as in heart failure
[25/06, 08:35]hu1: Got it thanks
[25/06, 08:36]hu1: So what should be the plan of action
Basically his problems are as below
Extremely lethargic
Feeling suffocated although spo2 and ecg seems okay as per cardiologist as long as it’s heartbeat isn’t too low or high
[25/06, 08:38]hu2: Sounds like heart failure
Does he also have pedal edema?
He needs good rest, diuretics as long as there is substantial pedal edema to reduce preload and ARBs to reduce afterload
[25/06, 08:39]hu1: Yes he has pedal edema
[25/06, 08:39]hu1: Will do
[25/06, 08:39]hu1: But I want him to be off ATT
[25/06, 08:39]hu1: Should I do it on our own without consulting chest people as they might not endorse this
[25/06, 08:41]hu2: We need to see his serial chest X-rays to rule in heart failure and rule out TB as the shadows of
11/6/26 is expected to keep changing rapidly and disappear with reduction in failure by now
[25/06, 08:42]hu3 (forwarded by hu1): Serial x ray?
[25/06, 08:49]hu3 (forwarded by hu1) : No CHF . We can repeat echo after a week or so for possible RV thrombus?
There was a tiny spec in RV
[25/06, 08:53]hu2: Serial chest X-ray would show lung changes of pulmonary edema recovery or worsening.
Echo may not help in this regard
[25/06, 08:54]hu2: Let's get a repeat chest X-ray now before that. I guess we.are going only by one single chest X-ray till now?
[25/06, 08:59]hu1: Yes that’s correct
Will try one today
[25/06, 11:44] Rakesh Biswas: Between these two transcripts can you insert the attached chest X-ray 👇
[24/06, 20:17]hu2: How was TB suspected?
What symptoms other than fever? Chest X-ray?
[24/06, 20:21]hu1: Pleural effusion unilateral
[01/09, 15:15] Rakesh Biswas: Viral fever heart failure ProJR patient conversational update from 29/6/26
[29/06/26, 18:21]hu1 : Just an update - his breathlessness continues
[29/06, 18:21]hu1: Yet to get his x ray - he doesn’t want to do it - but will soon prevail
[03/07/26, 09:15]hu1: Is it worth experimenting to infuse my (younger) Plasma to him?
[03/07, 09:15]hu2: No
[03/07, 09:16]hu2: It will cause further cardiac overload
[03/07, 09:28]hu1: If done 10 mL a day for 30 days?
[03/07, 09:30]hu2: This experiment needs IEC clearance
[03/07, 09:31]hu1: Have such case to case clearances been taken earlier in medical practice other than our grant and RCT trials
[03/07, 09:33]hu2: Yes off course
One published in Lancet I had shared with you earlier
[03/07, 09:36]hu2: https://pubmed.ncbi.nlm.nih.
[05/07, 05:39]hu1: What can I do to get him to move around - he feels immensely weak, even though his symptoms of breathlessness and cough seem to have receded…ATT?…we gave him multi vitamin drink-
he seems to have given up on living any more…sleeps the whole day and night …
[05/07, 07:16]hu2: Breathlessness and cough were part of the short term viral that precipitated his recent heart failure?
How is his wife? What does she feel about his depression?
[05/07, 07:25]hu1: Thanks-makes sense
Asked her-she doest feel so-he was depressed earlier and not any more
[15/07, 11:02]hu1: Ventilator is good for him?
[15/07, 11:02]hu1: His spo2 dipped to 85 today and increasingly feeling suffocated
[15/07, 11:03]hu1: He doesn’t want echo and x ray done ..but when I change his catheter I will try
[15/07, 11:03]hu1: Extremely weak and lethargic
[15/07, 11:03]hu2: Will need it if his hypoxia doesn't respond to oxygen but for that he'll need to be evaluated sos
[15/07, 11:05] hu2 : Home healthcare is best but these services are still not well established in India as of now.
Perhaps your team could be mobilized to work on this at a national scale
[15/07/26, 11:08]hu1: By an anesthesia or medicine consultant ?
[04/08/26, 13:32]hu1: Before and after the patient’s pleural tap
Cardiologist ruled out any CHF
[04/08, 16:59]hu2: It can't be ruled out.
[04/08, 13:32]hu1: Breathlessness continues after temporary relief
[04/08, 14:36]hu2: Can I give him 10 mg dytor in addition to below
[04/08, 16:57]hu2: 👆Date?
[04/08, 16:57]hu2: 👆Date?
[04/08, 16:58]hu2: Lasilactone contains frusemide and dytor is similar action aka torsemide
Can take additional lasix if necessary
Any pedal edema?
[04/08, 16:58]hu1: 4 days back
[04/08, 16:59]hu1: Same day after tap
[04/08, 17:00]hu1: Yes he has pedal edema
[04/08, 19:17]hu2: This is most likely to be heart failure
[04/08, 19:17]hu2: Can add tablet lasix also separately other than the lasilactone
[04/08, 19:21]hu2: Tablet lasix 40 mg at 12 PM if lasilactone is taken at 8:00AM
Can stop tablet lasix once pedal edema and breathlessness subsides
[04/08, 19:34]hu1: Why do cardiologist refuse to accept it asked so many times
[04/08, 19:35]hu1: For heart failure nothing is to be done? …perhaps nothing can be done
Anything we can do to reduce the risk or delay
[04/08, 20:51]hu2: Yes we are reducing the load on the heart with lasix and lasilactone (aka preload) and the afterload can be reduced with vasodilators
[04/08, 20:52]hu2: The idea behind heart failure treatment is to give rest to the heart and reduce it's pre and afterload
[04/08, 21:24]hu1: Ok
[04/08, 21:24]hu1: Thanks
[05/08, 04:18]hu1: What is pre and after load
[05/08, 04:38]hu1: Does it also mean that I don’t walk him to the dining table? He feels extremely exhausted and his heart beat reaches 110-115 when we make him walk
[05/08, 04:38]hu1: Saturation is maintained
[05/08, 04:39]hu1: Heparin injections are continuing
[05/08, 04:39]hu1: AFs accelerate CHF?
[05/08, 05:17]hu2: Yes
[05/08, 04:38]hu1: His average daily resting heart rate is around 90 or so
[05/08, 05:17]hu2: 70-80 would be better
Is he on any heart rate reducing agents?
[05/08, 05:18]hu1: Cardiologists say untill 130-150, we don’t treat
[05/08, 05:18]hu2: Tell them it's likely to be Hfpef
[05/08, 05:18]hu1: Should I take second opinion
[05/08, 05:19]hu2: You are already 🙂🙏
[05/08, 05:21]hu1: Cardiologist says nothing from my side as heart is fine
[05/08, 05:21]hu2ai: Low dose beta blockers to begin with and then if dose is uptitrated would help especially also for AF rate control
Low-dose beta-blockers provide initial, partial clinical benefits in heart failure with reduced ejection fraction (HFrEF), but maximum target doses established in clinical trials offer superior reductions in mortality and hospitalizations. [1, 2]
Disclaimer: This information is for general knowledge and should not be taken as medical advice. Always consult a local healthcare professional for diagnosis and treatment.
Efficacy and Dosing Dynamics •
Starting Point:
Therapy is initiated at a low dose to prevent potential initial worsening of heart failure symptoms as the body adjusts, minimizing risks of reduced adrenergic drive.
• Dose-Dependent Benefit: Clinical data consistently show that the reduction in all-cause mortality and heart failure readmissions is dose-dependent, with superior outcomes achieved when patients reach guideline-directed target doses.
• Titration Goal: Providers systematically increase the dose over time as tolerated, aiming for established target levels rather than maintaining a low dose. Low doses are considered a necessary, temporary phase for safe initiation, not the final therapeutic target. [2, 4, 5, 6]
AI responses may include mistakes.
[05/08, 05:24]hu2ai: Why does the heart appear fine in hfpef and how can a cardiologist be convinced to treat heart failure symptoms for such patients?
In Heart Failure with Preserved Ejection Fraction (HFpEF), the heart appears fine on a standard routine ultrasound (echocardiogram) because the ejection fraction (EF)—the percentage of blood pumped out of the main pumping chamber with each beat—is normal (usually 50% or higher). [1, 2, 3, 4, 5]
Why the Heart Appears "Fine"
• Normal Squeezing (Systole): The heart muscle squeezes and ejects blood normally, which tricks standard tests into looking healthy.
• Stiff Pumping Chambers (Diastole): The problem isn't the squeeze; it's the relaxation. The heart muscle has become stiff or scarred.
• High Pressures: Because it cannot relax properly to fill with blood easily, pressure backs up into the lungs and body, causing severe shortness of breath and fluid retention, even though the pump itself looks strong on the outside. [1, 6, 7, 8, 9]
How to Convince a Cardiologist to Treat HFpEF
Many cardiologists historically hesitated to treat HFpEF aggressively because older traditional heart failure drugs did not change survival rates. Today, modern guidelines have shifted. You can guide a productive discussion with a cardiologist by focusing on concrete evidence and modern therapies:
• Highlight Current Guidelines: Mention that modern clinical trials (such as those for SGLT2 inhibitors like empagliflozin or dapagliflozin) prove that targeted therapy reduces hospitalizations and improves symptoms in HFpEF.
• Use Clinical Scoring: Bring up validated tools like the H2FPEF score, which combines clinical features (obesity, age, hypertension, atrial fibrillation) with simple echocardiogram markers to calculate the mathematical probability of HFpEF.
• Ask for Advanced Testing: If resting echocardiograms are inconclusive, request specialized evaluations such as natriuretic peptide blood tests (BNP or NT-proBNP) or an exercise stress echocardiography / invasive hemodynamic test to expose elevated heart filling pressures during physical stress.
• Focus on Comorbidities: Emphasize aggressive management of the underlying drivers of the disease, including high blood pressure, obesity, diabetes, and sleep apnea. [19, 20]
To help tailor this advice, could you tell me:What specific symptoms (like shortness of breath or swelling) are most bothersome?What test results or feedback has the cardiologist provided so far?
AI responses may include mistakes.
[10] https://www.acc.org/latest-in-
[05/08, 05:25]hu1: This is the patient's video on a wheel chair
[05/08, 05:25]hu2: 👏nice so you managed to get that wheelchair you needed
[05/08, 05:26]hu1: Also got him roof display projector to watch movies which he watches as a duty, lying down
[05/08, 05:27]hu1: Would all of this help
[05/08, 05:27]hu2: All of?
[05/08, 05:28]hu1: Distractions
[05/08, 05:28]hu1: Diuretic you prescribed
[05/08, 05:29]hu1: Yes to be taken as long as there is visible pedal edema
What is his serum albumin?
[05/08, 05:32]hu1: Today we are repeating CBC and LFT as he is on empirical ATT
[05/08, 05:32] hu 1: Do you want to add a test like pro BNP or something
[05/08, 05:40]hu2: I'm fairly convinced about the heart failure and wouldn't need a pro BNP.
Also if it comes negative, the cardiologist will not be convinced in his her lifetime.
Approximately 20% to 33% of patients with confirmed heart failure with preserved ejection fraction (HFpEF) have a negative or normal NT-proBNP level (below standard rule-out thresholds like 125 pg/mL). [1, 2, 3]
Factors Increasing False-Negative NT-proBNP in HFpEF
• Obesity (BMI ≥ 30 kg/m²): Adipose tissue clears and suppresses natriuretic peptides, increasing false-negative rates significantly.
• Early or Mild Disease: Less myocardial wall stretch results in lower peptide release.
• Non-sinus rhythms or specific architectural variants: Preserved or unique ventricular-atrial remodeling can present with disproportionately low values. [1, 2, 4, 5]
Clinical Implication
A normal or negative NT-proBNP cannot safely rule out HFpEF if clinical suspicion remains high. Diagnosis typically requires correlation with echocardiography demonstrating diastolic dysfunction or elevated filling pressures. [2, 6, 7]
If you'd like, let me know:The patient's BMI / weight categoryWhether they are experiencing acute dyspnea or chronic symptomsAny other available echocardiogram findingsI can help outline further diagnostic steps or scoring tools used to evaluate suspected HFpEF.
AI responses may include mistakes.
[05/08, 05:44]hu1: Ok
[05/08, 05:45]hu1: BTW, His pro BNP levels were raised last time
[05/08, 05:48]hu2: Again clinical diagnosis in the head of the physician (aka medical cognition) reigns supreme and investigations may sway the physician if they are connected to a team based learning network where collective cognition plays a vital role in clinical decision making. Currently most physicians (cardiologists are also physicians albeit with less time to think) have barely time to think individually let alone collectively hence I wouldn't expect them to be convinced on the patient's advocate's persistence
[05/08, 05:49]hu1: His latest pleural tap results attached
[05/08, 05:49]hu1: Completely agree and aware of this
[05/08, 05:50]hu2: Very much suggestive of heart failure by Light's criteria of whatever information is available
Need serum and pleural fluid protein and LDH at the same time
[05/08, 05:51]hu1: And latest echo report
[05/08, 05:52]hu2: Very much Hfpef
LA dilatation even if just relative to the aortic root would have further sealed it
[05/08, 05:52]hu1: Ok
[05/08, 05:54]hu1: Pre load is the load on the heart before it contracts
Essentially the blood volume in the circuit and amenable to volume reduction with diuretics
Afterload is the aortic resistance offered to the heart after it contracts logically amenable to aortic vasodilators like ARBs like telmisartan etc
[05/08, 05:55]hu1: Got it thanks
[05/08, 05:58]hu1: To this at 8 am, we will add below at 12 pm
[05/08, 06:00]hu1: Hope it isn’t harmful to let him use oxygen concentrator set to 2 Units, as and when he feels breathlessness
So his suffocation comes from heart failure?
[05/08, 06:21]hu2: Yes
If his SpO2 is normal then oxygen may not be necessary and can be harmful
[05/08, 06:36]hu1: Ok
[05/08, 06:37]hu1: Then how to answer his call for “Ghutan ho rahi hai”
[05/08, 06:40]hu2: If SpO2 is normal then lasix or even NIV
[05/08, 06:41]hu2: Also one needs to check the respiratory rate first before taking any decision for intervention
[05/08, 06:45] hu 1: Spo2 is always above 90
[05/08, 06:48]hu1: respiratory rate is 18/20 as noted now
[05/08, 06:53]hu1: NIV will have to be recommended by cardiologist or pulmonary consultants?
[05/08, 07:25]hu1: It has to be above 92
[05/08, 07:26]hu2: So this is his baseline and it will be useful to check the rate when he complains of shortness of breath
[05/08, 07:27]hu2: Connecting to NIV is a complex decision to be handled by critical care physician and or pulmonology
[05/08, 18:47]hu1: He is feeling better Today
[06/08, 20:06]hu1: He is even better today ..less breathless
However, felt exhausted momentarily when I scored his RR which was 24, with above spo2 /heart rate, bp 112/74
[06/08, 20:07]hu1: 98/88
[06/08, 20:07]hu2: This would be expected with his heart failure
[06/08, 20:08]hu1: Momentarily his heart rate fell to 48 and in 3 secs rose to 88
[06/08, 21:42]hu2: That could sometimes be due to the sensor. Better verify with manual counting of the pulse in such situations
[07/08, 08:07]hu1: His bp fell to 105/67,!yesterday 112/74
[07/08, 08:08]hu1: It falls whenever we put him on double dose
Any change in Regimen
Pedal edema still there
[07/08, 08:13]hu2: That's expected. It means the medicine is working
Should be okay till it doesn't fall below 90/60
[07/08, 08:13]hu2: Pedal edema may take a few days to subside after which we can stop the second dose of the 13 PM lasix
[08/08, 09:49]hu1: Can nothing be done regarding his fatigue and exhaustion-can’t even walk to toilet
[08/08, 09:49]hu1: His Hb is 8.5
IV?
[08/08, 09:58]hu1: This is further precipitating his heart failure.
It's probably driven by his underlying CLL although one needs to rule out iron deficiency, although again his RBC indices do not suggest that except his RDW which is slightly raised.
A careful packed RBC transfusion could provide some symptomatic relief by taking care of cellular oxygenation that may reduce the current fatigue
[08/08, 09:59]hu1: Ok
[08/08, 09:59]hu2: IV only very slow prbc. Anything else will simply further load his heart and worsen his current symptoms.
[08/08, 09:59]hu1: Will discuss transfusion
[08/08, 10:00]hu2: Only slow prbc
[08/08, 11:44]hu1: Hematology say, "Yes, I can consider that after examining him. You may plan accordingly"
[08/08, 11:45]hu1: Does it require admission
[08/08, 11:47]hu1: Yes
[08/08, 11:48]hu1: Ok-does it carry risk?
[08/08, 16:05]hu2: Off course.
Mismatched blood transfusions can be fatal
[10/08, 12:02]hu1: Just sharing his pro BNP
[10/08, 12:08]hu2: I would not have changed my diagnosis even if it was normal
[10/08/26, 12:09]hu1: Ok
[01/09/26, 10:09]hu1: Which medicine you had prescribed at 12 pm?
[01/09, 10:09]hu1: Unable to dig out
[01/09, 10:09]hu1: As diuretic
[01/09, 10:49]hu2: Tablet Frusemide 20 mg
[02/09, 19:20]hu1: What to do when he is on morphine patch and asks for anxiety drug’s
[02/09, 22:36]hu2: Can give clonazepam 0.5 mg mouth dissolving for his anxiety
Also discuss with the psychiatry there
[03/09, 06:11]hu1: Ok
[03/09, 06:26]hu2: Since when is he on the morphine patch? Is it for pain? Where is the location of pain?
[03/09, 06:34]hu1: Yesterday only
[03/09, 06:35]hu1: upper right arm had excruciating pain which wasn’t reduced by pain killers, hot - cold fermentation. This shoulder has rotator cuff tear also. morphine patch helped
[03/09, 06:36]hu1: Are you thinking of heart
[03/09, 06:37]hu2: Yes morphine can help in heart failure too
Although the persistent pain is unlikely to be anginal in the absence of evolving ECG changes
[03/09, 06:38]hu1: Ok
I think it’s left arm not right though
[03/09, 06:43]hu2: Any serial ECGs?
[03/09, 06:43]hu1: Just to recap
Just to recap he is also on ATT, anti coagulants, AHs, diuretics and uric acid drug besides SOS clonazep/melatonin and anti spasmodics(for bladder) with by and large preserved LFT/RFT/electrolytes
[03/09, 06:43]hu1: Will do this
[03/09, 06:44]hu1: Most recent report👆
[03/09, 06:45]hu1: Shall continue this?-chest physicians said we can try increasing it if he tolerates. His pedal edema is gone-breathlessness comes and goes and asks for relief from it
[03/09, 06:46]hu1: Are you aware of something like a robotic arm so his hands can begin to function
[03/09, 06:49]hu2: Since when is his hands not functioning and why?
[03/09, 06:50]hu1: For 1.5 years because of massive shoulder cuff tear
[03/09, 06:51]hu1: his biceps are also split up-detached from broken kind-don’t know the clinical term
[03/09, 06:54]hu2: How frequently has he had the pain in last 1.5 years?
[03/09, 06:54]hu1: Recent pain came and went in last 4/5 months
[03/09, 06:55]hu1: 3-4 episodes
[03/09, 07:00]hu1: One episode in 6 months?
How many days did the previous episodes last?
[03/09, 07:01]hu1: 3-4 episodes in that period
[03/09, 07:01]hu1: It lasts for 6-7 days
[03/09, 07:04]hu2: So he is unable to move his right hand?
Can you share a video of his upper limbs to understand the current functioning?
[03/09, 07:04]hu1: Yes
I will do that
[03/09, 07:09]hu1: melatonin for sleep if needed at night
clonazepam for anxiety 0.25 half tablet sos
[03/09, 07:09]hu1: Psychiatrist clears this despite morphine…but ChatGPT red flags it
[03/09, 08:34]hu1: Will send video in evening
[03/09, 20:55]hu2: Thanks
I wonder why there is a disproportionate swelling in his left arm
[03/09, 21:33]hu1: Yes no one knows why
[03/09, 21:34]hu1: Pleural effusion was on right
[05/09, 14:57]hu1: I was hesitant to share this forward with the robotics enthusiast researcher who had earlier expressed interest as the identifiers were visible but he inquired again today and I just sent him personally asking him to delete it once he has seen
[05/09, 14:57]hu1: Ok thanks
[05/09, 15:01]hu3: Looks like a lymphedema as if something is blocking his lymphatic channels there.
Possibly an infiltration by his chronic leukemia cells again unknown at this point but a biopsy may confirm.
Unilateral hand swelling in chronic lymphocytic leukemia (CLL) is an extremely rare presentation that can be caused by direct leukemic infiltration of the hand tissues and bone or localized lymphatic complications. [1, 2]
Case Overview
• Patient Profile: Documented in medical literature (such as a reported 62-year-old man with a subclinical CLL history).
• Presentation: Chronic pain and swelling over the dorsal (back) surface of one hand, initially mimicking a localized infection.
• Clinical Challenge: Symptoms often show no response to broad-spectrum antibiotics or topical corticosteroids, and standard imaging can remain inconclusive.
• Diagnosis: Confirmed via tissue biopsy, which reveals direct infiltration or manifestation of the underlying clonal B-cell leukemia in the soft tissue or bone. [1]
Why It Happens
While CLL typically causes generalized or regional lymphadenopathy (swollen lymph nodes in the neck, armpits, or groin), atypical extramedullary manifestations or leukemic cell skin/bone infiltration can occasionally target distal extremities like the hand. Other rare causes of unilateral hand swelling in cancer patients include secondary lymphedema or localized vasculitis. [1, 2, 3, 4, 5, 6]
[05/09, 19:37]hu2: From our robotics researcher: His right "hand" does not need any augmentation. From what I understand
The right shoulder RoM needs assistance. He's using his left hand for the support
[05/09, 19:37]: A very gentle apparatus that will assist through that section is all that is needed.
[05/09, 19:41]hu2: Any investigations were done for the shoulder cuff tear?
[05/09, 20:10]hu1: MRI showed complete rotator cuff tear both shoulders with joint effusion
[05/09, 20:18]hu2: 1.5 years back rotator cuff
When was the CLL first diagnosed?
[05/09, 20:31]hu1: Trying to think
[06/09, 09:02]hu2: .
More than that:
Clinical re-evaluation of the pleural effusion (in light of recent video showing his left upper limb) to figure out if this pleural effusion is due to leukemic infiltration.
Repeat pleural fluid protein LDH with serum protein LDH and pleural fluid cytology etc
Again getting the accurate diagnosis here may not really solve his current issues though
So a fresh list of his current priority problems in terms of what are his actual symptomatic concerns is what we need to prepare first
[06/09, 09:04]hu1: Regardless of above(which I will seek) shall I increase his dose of diuretics
His breathlessness has increased
[06/09, 09:05]hu1: Pleural effusion cytology continues to remain negative in all possible fronts(did this excercise thrice in last 4 months)
[06/09, 09:06]hu2: Yes it doesn't have good sensitivity anyways and may not be able to rule out anything
[06/09, 09:07]hu2: Can because if this is heart failure he will feel better but if this is due to pleural effusion due to leukemic infiltration then tapping the pleural fluid and then doing a pleurodesis may be a better option
[07/09, 06:44]hu1: Getting him to stimulate vagal tone
[07/09, 06:45]hu1: He doesn’t want to do anything
When I visit him in morning I try to engage him something
[07/09, 07:18]hu2: Excellent! Reminds me of BK Iyengar's global initiative to promote yoga props.
Did we discuss this at some point previously to take it up as a project especially for the elderly?
[11/09, 12:38]hu1: Got his tap done -750 mL although pulmonologist cautioned about not getting it done repeatedly for possible infections
[11/09, 12:38]hu1: His cath was changed today
[11/09, 12:38]hu1: After tap
[17/09, 17:04]hu1: His RR is 23, spo2 95/84
[17/09, 17:04]hu1: On ATT
[17/09, 17:10]hu1: Shall I try HBOT
[17/09, 17:54]hu1: Not indicated in his situation
One can try NIV
[17/09, 18:02]hu1: Ok - chest physician continues to say not needed, saying if needed we can get it on rent
May be I will try on rent first
[17/09, 18:03]hu2: Yes let's try it on rent
[17/09, 22:14]hu1: Can his bed sore be cleaned from spirit, h2o2 and betadiene
[17/09, 22:15]hu1: above is an experience and question shared by my chacha ji while nursing my grand mother
[18/09, 07:58]hu2: Need to see the picture of the bed sore
Check out an experience here 👇
Scroll down for the bed sore
[20/09, 07:24] hu1: This is his bed sore picture
[20/09, 11:24]hu2: It's a pressure sore due to prolonged posturing due to lack of mobility.
Has he been bedridden since the last few weeks?
The passive movements that you were doing in the chair would have been useful although actively moving his toes would help better although again I'm not currently aware of what his sensorium is like and if he will be able to move his toes.
Unless there is movement the microcirculation of the skin doesn't improve and the sore may not heal
[20/09, 12:07]hu1: He is conscious and will do what you suggested
[20/09, 12:07]hu1:Also getting him NIV today on rent before buying
[20/09, 14:25]hu1: Heart rate dropped and he slept off instantly at 8/4 setting
[20/09, 14:25]hu1: Advised by chest physician
[20/09, 14:58]hu1: His RR is now 16
[20/09, 20:17]hu1: Despite all efforts his air hunger continues as soon as he is out of NIV and even efforts to distract his attention keep failing
I think he simply doesn’t want to live
There is no way to get his pleural fluid out ?
[20/09, 20:23]hu2: The pleural fluid may not be responsible for the air hunger but yes one can try tapping it and inserting an intercostal tube. Very often done by pulmonologists.
Also if it turns out to be due to leukemic infiltration (as per a similar case report shared with you earlier), one could even offer some solution from Hematology
[21/09, 07:04]hu1: Good morning,
Advice from Hematology:
breathlessness can be eased with a blood transfusion after checking the latest Hb. Chemo is not indicated at present. His leucocytes are already on the lower side and Hb will also decline
[21/09, 07:04]hu1: Hematology
[21/09, 07:30]hu2: Agree about the harms of chemotherapy.
Although not sure about the breathlessness can be eased with the blood transfusion part.
Pulmonologist opinion for thoracoscopic biopsy and inter costal tube drainage with pleurodesis if necessary after thoracoscopic assessment could be one way forward
[21/09, 07:45] hu1: What are you suspecting for biopsy
[21/09, 07:51]hu1: CLL infiltration
[21/09, 07:52]hu1: Pleural fluid cytology and entire work up thrice in previous occasions revealed nothing
[21/09, 07:52]hu1: I think biopsy is different isn’t it
[21/09, 07:54]hu2: Yes biopsy is more definitive
[21/09, 07:54]hu1: https://www.
[21/09, 20:49]hu1: His spo2 is beginning to drop to below 90 now, w/o NIV/o
[21/09, 20:50]hu1: Yes that means he will need NIV again
[21/09, 20:50]hu1: Has it happened because he became habituated to NIV
[21/09, 20:51]hu2: No it's largely due to his lung infiltration either by CLL or because of the heart failure
[21/09, 20:50]hu2: Any drugs he's on that can cause the dizziness?
[21/09, 20:51]hu1: sOS Valium
[21/09, 20:51]hu1: Clonazepam
[21/09, 20:51]hu2: When did he take those last?
What's his latest serum creatinine?
[21/09, 20:52]hu1: Let me ask
[21/09, 20:53]hu1: He took Valium 1.25 mg now, not the whole day not even clonazepam
[21/09, 20:53]hu2: What about yesterday?
Also his serum creatinine?
[21/09, 20:54]hu1: A creatinine was in range
[21/09, 20:54]hu1: When was it done last?
[21/09, 20:55]hu1: Since when was he first started on nexito?
[21/09, 20:57]hu2: 31st August creatinine looks good
[21/09, 21:13]hu1: Psychiatrist feels we stop clonazep
[21/09, 21:30]hu1: His wife just told he took Valium 1.25 mg plus clonazep within last 2 hours
[21/09, 21:30]hu1: What can be done at this stage
[21/09, 22:16]hu1: Hematology consult:
I am not sure how it will help to have a biopsy
If malignancy - unfit for chemo as per sir
If tb - he is already on treatment
If neither - partly heart failure and anemia contributing
Which needs to be addressed anyway
I m not sure how the biopsy according to him will help
[22/09, 11:53]hu2: I'm heartened to see this assessment.
We can also say that given his condition he could be unfit for a thoracoscopic biopsy as well.
I agree, if we do not want to be energetic on the treatment of malignancy especially with systemic chemo it's fine.
And if we want to be energetic, one could explore other options in terms of intrapleural installation of biologics?
[22/09, 11:54]hu2: His unilateral lymphedema that I spotted on his upper limb images, makes me strongly suspect that it's a leukemic infiltration and could be tackled locally if not systemically but I also agree it's very challenging to do so
[22/09, 12:00]hu1: This is reassuring ..and will discuss
[22/09, 21:55]hu1: Platelet fell from 278 to 106
[23/09, 07:14]hu2: He's having pancytopenia now with low rbc, wbc and platelets
[23/09, 07:15]hu1: Yes thought so-how approach will change
[23/09, 07:16]hu2: This indicates possible infiltration of bone marrow due to CLL infiltration.
Has he had a bone marrow biopsy done earlier?
[23/09, 07:25]hu1: Ok-No, not bone marrow-only nodules were biopsied
[23/09, 07:25]hu1: Will blood transfusion help?
[23/09, 07:30] hu2: No
[23/09, 07:32]hu1: Was thinking if we could design studies to reverse these processes
[23/09, 07:33]hu2: The best study design is to treat every patient as a separate clinical complexity project!
[25/09, 21:43]hu1: Meanwhile today was eventful with father in distress repeatedly HR continued to hover 112-150; sweating and preserves bp, very breathless, spo2 occasionally fell to 66-67: Holter report on Monday
[26/09, 08:01]hu2: This description sounds like heart failure
[25/09, 21:44]hu1: ABG report - anything you think needs to be done
[26/09, 07:59]hu2: Doesn't look that bad. How much oxygen was he on while this ABG was drawn?
[26/09, 08:19]hu1: He wasn’t on oxygen
[26/09, 09:48]hu2: Oh then it looks quite good as there's no hypoxia!
He just has hyperventilation with respiratory alkalosis being compensated with mild metabolic acidosis
[26/09, 04:29]hu1: Is this a situation to take him to emergency or let him rest in peace( such an unethical question)
[26/09, 08:01]hu2: It's not an ethics question but the oldest research question in medicine.
We just need to make sure that our cure is not worse than the natural outcome of the illness
[26/09, 11:45]hu1: His current BP is 70/45
[26/09, 11:46]hu2: Is this hypotension cardiogenic or sepsis related?
Can be ascertained through currently more invasive means but as suggested by the pulmonologist I guess we need to intervene less at this point and just be with the patient
[26/09, 11:48]hu1: Shall I administer a drip
[26/09, 11:48]hu2: Any symptoms?
[26/09, 11:48]hu1: He is sleeping
[26/09, 11:51]hu1: None
[26/09, 11:51]hu1: Normal sleep? Is he arousable?
[26/09, 11:54]hu1: A bit drowsy
[26/09, 11:57]hu1: Oxygen abhi lagaya
[26/09, 11:57]hu2: The ABG was without oxygen but the oxygen appears to have been started inspite of the patient's having shown no hypoxia on ABG?
[26/09, 11:57]hu1: Oxygen was 76/86
[26/09, 11:57]hu1: Now going up
[26/09, 11:58]hu2: Let's hope he'll wake up once his hypoxia is better
[26/09, 11:59]hu2: Shall I put a drip or get x ray/usg
[26/09, 11:59]hu2: Can start a drip with normal saline at 100 ml per hour
[26/09, 15:08]hu1:BP looks better
[26/09, 16:28]hu2: After saline?
[26/09, 19:40]hu1: Saline not given
[26/09, 19:40]hu1: It came up on its own
[26/09, 23:08]hu1: Now that every time I remove oxygen spo2 falls to 70s..should NIV be used?
[27/09, 06:47]hu1: Decided to give 2 hrs NIV each day morning and evening
[27/09, 06:49]hu1: Got a back up cyclinder after there was power outrage and the contractor didn’t function
[27/09, 07:32]hu2: Yes can use NIV as this is a pulmonary parenchymal problem either due to heart failure driven alveolar edema or due to leukemic infiltration.
If heart failure it can respond to diuretics and aortic vasodilators but if due to leukemic infiltration it won't
[27/09, 07:33]hu2: You mean you already had an oxygen concentrator at home?
[27/09, 08:34]hu1: Yes
[27/09, 08:35]hu1: He pulls out his oxygen pipe often and spo2 falls to 69-71
[27/09, 08:36]hu1: Could he be doing it voluntarily-if we stop him he is so angry
I have a feeling he wants to go but I may be wrong
[27/09, 09:45]hu2: Ask him. I'm sure he will be able to hear you and respond to what he really needs.
I too agree with less invasive options and just being there with him actively trying to discern his own felt needs rather than what other currently limited collective scientific cognition may dictate
[27/09, 09:46]hu1: Sounds good thanks
[27/09, 17:00]hu1: Got pigtail done and he is greatly relieved
[27/09, 19:00]hu2: Who put it in? Pulmonologists?
[27/09, 19:00]hu1: Yes after cardiologists kind of showed heart was perfect they yielded
[27/09, 19:00]hu1: And after seeing the state of lung
[28/09, 07:41]hu2: Massive pleural effusion documented on CT chest prior to pigtail insertion?
[28/09, 07:41]hu1: Yes this is prior to pigtail
[28/09, 07:42]hu1: He is able to talk back intermittently now
[28/09, 07:43]hu1: I have litres of pleural fluid-what all should we investigate
Is it really CHF causing it
Is it some undetected infection
Are these infiltrates?
[28/09, 07:43]hu1: Could it have happened after we stopped ATT?
[28/09, 07:58]hu2: Pleural fluid for tlc, dlc
(Cells need to be seen fresh else they will appear disfigured on the microscope)
Pleural fluid for protein, LDH along with serum protein and LDH to determine if it's transudate (heart failure) or exudative (inflammatory)
[28/09, 07:59]hu2: If the pleural effusion was due to tuberculosis then yes but from what data we have shared earlier it didn't appear to be tuberculosis as the pleural fluid didn't reveal any inflammatory characteristics
[29/09, 09:56]hu1: A million dollar question is whether we should restart ATT
[29/09, 10:01]hu1: Earlier also it was started empirically only
Only thing being the rapid accumulation of pleural fluid was coincidental with withdrawal from ATT
[29/09, 10:06]hu2: It was a coincidence I'm sure
[29/09, 10:07]hu2: We can't attribute causality based on the coincidence
[29/09, 10:08]hu2: Leukemic infiltration is more likely especially given his right upper limb lymphedema.
Ask the surgeons if they can take any biopsy from that region of the limb to demonstrate lymphatic infiltration by the leukemia
[29/09, 10:10]hu1: And also an interesting observation
That particular arm has suddenly show receding edema which remained locked from all previous prescriptions
[29/09, 10:10]hu2: Even the dermatologist can also help to get a skin biopsy that may reveal the infiltration 👇
[29/09, 10:10]hu2: Yes even this phenomenon is mentioned in leukemic infiltration
[30/09, 09:09]hu2: How's he feeling subjectively?
Objectively what's his current oxygen requirement and SpO2 on room air?
What is the daily volume of pleural fluid output from the pigtail drain?
[30/09, 09:10]hu1: From yesterday he was a bit down as compared to first day and I was wondering why
[30/09, 09:10]hu1: Oxygen in his own but yes it kind of dropped to 88-89 and he often asked for NIV
[30/09, 09:10]hu1: No output since 48 hrs
May be it’s blocked or requires more streptokinase or filled up again that rapidly?
[30/09, 09:11]hu2: A bedside ultrasound could throw more light
[30/09, 09:15]hu1: A lot of septae (while showing the ultrasound image)
[30/09, 09:22]hu2: That's common in an exudative pleural effusion
Clinically looks like leukemic infiltration
[30/09, 09:49]hu2: His serum creatinine has increased.
An 86-year-old man with a serum creatinine of 1.83 mg/dL has an eGFR of approximately 35.5 mL/min/1.73m². This is calculated using the standard, race-free 2021 CKD-EPI equation, which is the current clinical benchmark recommended by the National Kidney Foundation. If his lab still utilizes the older 2009 CKD-EPI formula, the result is 32.7 mL/min/1.73m².
Staging and Clinical Significance
Both values fall squarely into Stage 3b Chronic Kidney Disease (CKD), which represents a moderate-to-severe decrease in kidney function (range: 30–44 mL/min/1.73m²)
[30/09, 10:09]hu1: He has a very negligible leukemia load. Clinically it is quite unlikely.
The only way to be sure will be biopsy which I would not recommend at this point and in this state of health.
[30/09, 10:09]hu1: Above note from his Hematology team
[30/09, 10:12]hu1: Could the pleural effusion be linked to kidney failure
[30/09, 10:49]hu2: The renal failure is likely due to his systemic illness and medications side effects
[30/09, 10:50]hu2: Yes thoracoscopic pleural biopsy may not be feasible.
What about a dermatologist or cytologist's evaluation for a quick fnac or tissue biopsy from his lymphedema hand?
[30/09, 10:50]hu1: But is it really renal failure
[30/09, 10:51]hu2: It could be pre renal failure too
[30/09, 10:54]hu2: This gfr can be classified as "Moderate to severe loss of kidney function" while failure can be labelled as a GFR less than 15
[30/09, 10:56]hu2: Treatment in this condition particularly for the renal loss would be mainly supportive taking care to prevent further loss by screening for any nephrotoxic inputs in terms of his medications and maintaining strict intake output charting of his fluid balance
[30/09, 10:56]hu1: Ok
[30/09, 10:58]hu1: He is on suprapubic cystostomy SPC
On USG echogenicity and size of kidney okay
[30/09, 10:58]hu2: Yes post renal causes such as SPC could also be responsible for his lower eGFR
[30/09, 10:59]hu2: USG echogenicity and size are markers of advanced gross renal failure
[30/09, 11:04) hu1: Basically morning towards multi organ failure ?
[30/09, 11:05]hu2: Possibly
[30/09, 11:18]hu2: When was the last chest CT done?
[30/09, 11:18]hu1: This Sunday
[30/09, 14:24]hu2: Yes hence the marked area of suspicion in the chest X-ray is unlikely to have been missed in that HRCT
[01/10, 07:24]hu1: Could this accumulation of pleural fluid be a result of heparin injections
[01/10, 07:34]hu2: The intrapleural heparin if it was instilled through the intercostal pigtail would have intended to free up loculated areas and make them drain better.
[01/10, 07:35]hu1: He is on heparin for 2/3 months due to AFibs
[01/10, 07:35]hu1: We are injecting streptokinase IP
[01/10, 07:38]hu2: People have tried intrapleural heparin too albeit in their animal labs 👇
[01/10, 07:39]hu2: No heparin has never been reported to cause pleural effusion as a side effect
[01/10, 09:10]hu1: Total injections 3
Output 2 Ltres
[01/10, 09:10]hu1: Collected fresh pleural fluid
[01/10, 09:10]hu1: Would you like to call for additional tests
[01/10, 09:14]hu2: I guess most of it has been done
We just need to reconfirm if it's exudative using the pleural fluid protein and LDH alongside his serum protein and LDH ratios while cytology can be tried for the umpteenth time to look for leukemic infiltration although biopsy would have a better chance
What about his hand cutaneous biopsy with the dermatologist?
[01/10, 09:24]hu1: So biochemistry and biopsy
Will work on this thanks
[01/10, 15:07]hu1: AFB is negative
[01/10, 15:07]hu1: Fungal smear shows epithelial cells
[01/10, 15:07]hu1: Culture report to be followed
[01/10, 15:08]hu2: 👆most of these results are expected
What we need is to chase the leukemia currently suspected to have reached the pleura
[01/10, 15:09]hu1: Yes chasing that
[01/10, 19:33]hu1: CD19, C20 positive with kappa restriction.
CD 10 heterogenous.
[01/10, 19:33]hu1: Looks like Mature B cell Lymphoma
[01/10, 19:33]hu1: Seems high grade B lymphoma. But, a leukemia is not completely out due to low levels of CD20.
[01/10, 19:40]hu2: These are pleural fluid findings?
[01/10, 19:44]hu1: So it’s good to have diagnosis and obviously a poor prognosis
[01/10, 19:48]hu2: So it is a leukemic or lymphomatoid infiltration of the pleura
Yes let's ask the hematology team if they can try anything for palliation like the previous suggested intrapleural biologics in the link here 👇
[01/10, 19:50]hu2: It would be nice if I could see a video of his echocardiography
[01/10, 19:57]hu1: I was wanting to do this but didn’t
[01/10, 19:57]hu1: Let me revert soon
PaJR group CDSS:
[02/10, 22:17]hu2: Here's his layered case report primarily created from past dyadic conversations with his advocate for you to add to your database 👇
https://medicinedepartment.blogspot.com/2026/10/layered-case-report-elderly-man-with.html?m=1
[02/10, 22:18] PaJR Health Bot Feb 26: Added to the de-identified case record.
The update preserves:
▪️ The layered PaJR structure: day-to-day care dialogue, structured case interpretation, and ProJR cross-case learning.
▪️ The recurrent right multiseptated pleural effusion requiring pigtail drainage.
▪️ The competing cardiac, lymphatic, infectious, renal and lymphomatous explanations.
▪️ The new pleural-fluid finding: clonal mature B-cell population, CD19+, CD20+ low/variable, kappa-restricted and heterogeneous CD10.
▪️ The unresolved distinction between CLL/SLL involvement, transformed/high-grade lymphoma and multifactorial effusion.
▪️ Frailty, anaemia, cytopenias, renal impairment, oxygen/NIV dependence and the need for symptom- and goal-directed management.
▪️ The key diagnostic and management uncertainties for future review.
The report has been incorporated as clinical context, not as independent confirmation of every historical statement or treatment decision.
[03/10, 08:09]hu2: Today's PaJR group update :
[03/10, 06:48]hu1: Wonder how and why this edema disappeared in conjunction with pig tail drainage of R/lung
[03/10, 07:25]hu2: Because it's a lymphedema where the hand lymphatic channels are connected with the pleural lymphatic channels as hinted at in yesterday's case report?
[03/10, 08:12]hu2:
[03/10, 06:50]hu1: Yesterday pig tail was blocked(stuck to some consolidation/clot identified by USG) and we again went to IR to reposition it and 1+1 litre came out
[03/10, 06:50]hu1: Last evening scan
[03/10, 07:35]hu1: Oh yes how did I miss this
Should we try in his case?
Sharing with hematology prof and he is planning to admit him
Do you think CAR T might help
Him or are these efforts not worthy of investments vis a vis the same investment into younger folks
Our local hospital has a CAR T therapy RCT going on
[03/10, 07:36]hu1: It’s the same one you sent earlier
[03/10, 07:37]hu2: Yes
[03/10, 07:37]hu2: It's still experimental
[03/10, 07:47]hu2 with Gemini 2.5 flash lite: Systemic CAR T-cell therapy can traffic into pleural spaces and target leukemic infiltrates, though efficacy depends heavily on the specific antigen expression and local microenvironment barriers.
## Overview of Leukemic Pleural Infiltration
* Definition: Involvement of the pleura (the membrane)... continued below
[03/10, 08:20]hu2:
[03/10, 07:47] hu2 Gemini 2.5 flash lite: Systemic CAR T-cell therapy can traffic into pleural spaces and target leukemic infiltrates, though efficacy depends heavily on the specific antigen expression and local microenvironment barriers.
## Overview of Leukemic Pleural Infiltration
* Definition: Involvement of the pleura (the membranes surrounding the lungs) by leukemic cells, often leading to malignant pleural effusion.
* Challenge: Extranodal and sanctuary site involvements like pleural infiltrates can sometimes display altered penetration or persistence compared to circulating blasts or bone marrow.
## Efficacy of Systematic CAR T-Cell Therapy
* Systemic Trafficking: Intravenously administered CAR T-cells (systematic delivery) can traffic from the bloodstream into extravascular and serous fluid compartments, including pleural effusion sites, as documented in clinical monitoring and case studies.
* Antigen Targeting: For B-cell malignancies (like B-ALL or lymphoma) involving the pleura, CD19- or CD22-targeted CAR T-cells can induce profound local responses and clear pleural infiltrates, though persistent effusions can occasionally linger due to post-treatment inflammation or cytokine release syndrome (CRS) effects. [1]
* Barriers: Solid tumor pleural infiltrates (or myeloid leukemias like AML) face greater hurdles due to immunosuppressive pleural microenvironments, antigen heterogeneity, and variable T-cell trafficking efficiency. [2]
[1] [https://pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41062320/)
[2] [https://www.nature.com](https://www.nature.com/articles/s41408-026-01544-5)
[03/10, 07:49]hu2 Gemini 2.5 flash lite: In Chronic Lymphocytic Leukemia (CLL), systemic CD19-targeted CAR T-cell therapy can successfully track into extramedullary compartments, including the pleural space, but its overall clinical efficacy faces distinct biological headwinds compared to other B-cell malignancies. [1, 2]
## Efficacy Data for CAR T-Cell Therapy in CLL
*
* Response Rates: Systematic clinical data shows a pooled Overall Response Rate (ORR) of approximately 61% and a Complete Response (CR) rate of roughly 29%. [3, 4]
* Deep Clearances: The therapy achieves an impressive undetectable Measurable Residual Disease (uMRD) rate of around 71%, showing it can eradicate low-level systemic disease very effectively. [5]
* Durability Challenges: The median progression-free survival (PFS) sits around 12 months, meaning long-term response durability remains a primary clinical focus. [5, 6]
*
## Dynamics of Treating Leukemic Pleural Infiltration in CLL
*
* Pleural Trafficking: Systemically administered CAR T-cells cross the endothelial barrier to accumulate directly inside malignant pleural fluids, actively targeting CD19-positive CLL cells in the pleura. [2]
* Pre-Treatment Effusion Risks: Studies suggest that having a pre-existing malignant pleural effusion before starting CAR T-cell therapy increases the risk of severe toxicities, non-relapse mortality, and localized fluid complications. [7]
* Pleural-Localized CRS: As CAR T-cells encounter leukemia cells within the pleural space, they can spark a localized Cytokine Release Syndrome (CRS). This localized immune battle can cause a temporary spike in pleural fluid volume or prolonged, unilateral effusions that require medical management or drainage, even while the leukemia cells are successfully being cleared. [2, 8, 9]
*
## Overcoming CLL-Specific Barriers
*
* T-Cell Exhaustion: CLL patients frequently present with baseline T-cell dysfunction and exhaustion, which can impair the quality of the manufactured CAR T product.
* Optimising Outcomes: Utilizing bridging strategies with BTK inhibitors (like ibrutinib) or BCL-2 inhibitors (venetoclax) prior to cell collection is often used to optimize T-cell fitness, manage tumor burden, and improve the survival and expansion of CAR T-cells inside sanctuary sites. [10, 11, 12, 13]
[1] [https://pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178044/)
[2] [https://pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41062320/)
[3] [https://ashpublications.org](https://ashpublications.org/blood/article/146/Supplement%201/2740/549534/Efficacy-of-CAR-T-cell-therapy-in-chronic)
[4] [https://cllsociety.org](https://cllsociety.org/2026/05/efficacy-of-car-t-therapy-for-chronic-lymphocytic-leukemia/)
[5] [https://cllsociety.org](https://cllsociety.org/2026/05/efficacy-of-car-t-therapy-for-chronic-lymphocytic-leukemia/)
[6] [https://www.sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/S0006497125054874)
[7] [https://pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33781520/)
[8] [https://pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5839873/)
[9] [https://www.researchgate.net](https://www.researchgate.net/publication/396326842_Persistent_Unilateral_Pleural_Effusion_with_Chimeric_Antigen_Receptor_T-cell_Infiltration_in_Primary_Mediastinal_Large_B-cell_Lymphoma)
[10] [https://www.vjhemonc.com](https://www.vjhemonc.com/video/yonno07_ecc-the-current-status-of-car-t-cell-therapy-in-cll/)
[11] [https://my.clevelandclinic.org](https://my.clevelandclinic.org/podcasts/cancer-advances/the-potential-of-car-t-cell-therapy-for-chronic-lymphocytic-leukemia-cll)
[12] [https://www.vjhemonc.com](https://www.vjhemonc.com/video/u7plmeqndyo-t-cell-dysfunction-in-cll-and-implications-for-car-t/)
[13] [https://www.vjhemonc.com](https://www.vjhemonc.com/video/yonno07_ecc-the-current-status-of-car-t-cell-therapy-in-cll/)
[03/10, 07:51] hu2 Gemini 2.5 flash lite: When managing a symptomatic pleural effusion (causing shortness of breath, cough, or chest pain) in a Chronic Lymphocytic Leukemia (CLL) patient undergoing or preparing for CAR T-cell therapy, the approach requires careful, time-sensitive coordination. [1, 2]
How the effusion is managed depends heavily on whether it is a pre-existing condition or if it developed newly after the CAR T-cell infusion. [3, 4]
## 1. Pre-Existing Pleural Effusions (Before CAR T-Cell Infusion)
If the symptomatic effusion is present before lymphodepleting chemotherapy or CAR T-cell infusion, active clinical intervention is highly prioritized. [3, 4]
*
* High Clinical Risks: Clinical data indicates that patients with pre-existing, malignant pleural effusions face a higher rate of severe (Grade 3+) Cytokine Release Syndrome (32%) and decreased overall survival. The fluid acts as a local reservoir where explosive CAR T-cell expansion can trigger localized "compartment" CRS. [3, 4, 5]
* Management Strategy:
* Interventional Drainage: Mechanically draining the fluid via ultrasound-guided thoracentesis or placing a temporary chest tube is routinely performed to optimize the patient’s respiratory baseline.
* Bridging Therapies: Effective systemic bridging with targeted therapies (e.g., BTK or BCL-2 inhibitors) can drastically reduce cellular burden in the pleura before CAR T execution. [6, 7]
*
## 2. New Post-Infusion Pleural Effusions (After CAR T-Cell Therapy)
If an effusion develops or rapidly worsens after the CAR T-cells are infused, it is typically driven by an immune-mediated process rather than progressive leukemia. [3, 4]
*
* The "Compartment CRS" Phenomenon: When CAR T-cells traffic into the pleural space and encounter CLL cells, they release massive quantities of localized cytokines (like IL-6). This causes extreme capillary leakage, filling the pleural space with fluid. [5, 8]
* Management Strategy:
* Medical Management First: Unlike pre-existing effusions, new post-infusion effusions generally resolve without aggressive chest tubes. They are managed medically with tailored systemic corticosteroids (such as dexamethasone) and targeted IL-6 blockers like [tocilizumab](https://www.ncbi.nlm.nih.gov/books/NBK585093/).
* Watchful Monitoring: These effusions can sometimes look massive on a CT scan or X-ray but are frequently transient and resolve spontaneously once the localized immune battle settles. Interventional tapping is reserved strictly for severe respiratory distress. [3, 4, 9, 10, 11]
*
| Effusion Timing | Primary Cause | Severity & Toxicity Risk | Primary Management Path |
|---|---|---|---|
| Pre-Existing (Pre-CAR T) | Active leukemic infiltration | High risk of severe systemic CRS | Mechanical drainage (thoracentesis) + bridging therapies |
| Newly Arising (Post-CAR T) | Localized immune activation / capillary leak | Variable; usually transient and localized | Medical stabilization (Corticosteroids, Tocilizumab) |
[1] [https://pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC4753987/)
[2] [https://www.pennmedicine.org](https://www.pennmedicine.org/conditions/pleural-effusion)
[3] [https://www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S2666636720300993)
[4] [https://www.astctjournal.org](https://www.astctjournal.org/article/S2666-6367%2820%2930099-3/fulltext)
[5] [https://pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5839873/)
[6] [https://my.clevelandclinic.org](https://my.clevelandclinic.org/health/diseases/17373-pleural-effusion)
[7] [https://www.youtube.com](https://www.youtube.com/watch?v=XaqsqtWiJMw)
[8] [https://onco-hema.healthbooktimes.org](https://onco-hema.healthbooktimes.org/article/116250-rare-adverse-events-of-car-t-cell-therapy)
[9] [https://pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12174263/)
[10] [https://www.researchgate.net](https://www.researchgate.net/publication/396326842_Persistent_Unilateral_Pleural_Effusion_with_Chimeric_Antigen_Receptor_T-cell_Infiltration_in_Primary_Mediastinal_Large_B-cell_Lymphoma)
[11] [https://pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9772271/)
[03/10, 07:54]hu2 with Gemini 2.5 flash lite:
Managing a symptomatic pleural effusion during the planning phase as an outpatient is a critical window to optimize the patient's respiratory health and reduce the risk of severe complications before they transition to the inpatient CAR T-cell infusion.
## Core Management Plan for the Outpatient Planning Phase
* Urgent Pulmonary Optimization: Because a pre-existing effusion increases the risk of severe, localized Cytokine Release Syndrome (CRS), the care team will prioritize draining the fluid. This is typically done via an outpatient ultrasound-guided thoracentesis. For recurrent fluid buildup, a temporary indwelling pleural catheter (IPC) may be placed so the fluid can be managed at home.
* Aggressive Bridging Therapy: To actively reduce the leukemic burden in the pleura while the CAR T-cells are being manufactured, the oncologist will likely utilize targeted bridging agents. Continuing or initiating BTK inhibitors (like ibrutinib) or BCL-2 inhibitors (venetoclax) helps shrink the pleural infiltration, which directly lowers the intensity of post-infusion immune reactions.
* Close Symptom Monitoring: As an outpatient, strict tracking of respiratory changes is mandatory. The patient should have a low threshold to contact the care team or go to the emergency department for worsening shortness of breath, a new cough, or chest pain.
## Key Pre-Admission Action Items
* Pulmonary Function Check: Ensure the patient has a recent pulmonologist evaluation to confirm their lungs can tolerate the upcoming lymphodepleting chemotherapy.
* Fluid Drainage Timing: Coordinate the therapeutic thoracentesis as close to the admission date as clinically safe to ensure the pleural space is as dry as possible before cell infusion.
* Logistical Planning: Verify the outpatient caregiver structure, as the patient will need close monitoring for symptom changes during the bridging window.
To help tailor this timeline, do you know how long the manufacturing window is expected to be, or when the scheduled admission date for the infusion is?
[03/10, 08:21] PaJR Health Bot Feb 26: The CAR‑T discussion is *biologically plausible but clinically overconfident in several places*.
*WHAT THE CURRENT DATA SUPPORTS*
▪️ Pleural fluid contains *CD19-positive, kappa-restricted mature B cells*. Therefore, a CD19-directed therapy could theoretically target the pleural malignant population.
▪️ The reduction in hand/arm oedema after pigtail drainage is an important observation, but it does *not prove a direct lymphatic connection* between the arm and pleural space. It may reflect reduced thoracic pressure, improved venous/lymphatic drainage, or redistribution of fluid.
▪️ Systemic CAR‑T cells can reach extravascular disease, but evidence specifically proving reliable control of CLL-related pleural disease is limited. The pleural space should not automatically be labelled a “sanctuary site” with predictable CAR‑T activity.
*WHAT SHOULD NOT YET BE ASSUMED*
1. The quoted CLL CAR‑T response rates cannot be directly applied to this patient. Outcomes are strongly affected by age, performance status, organ function, prior treatment, disease burden, T-cell fitness and whether the disease is actually CLL/SLL or transformed lymphoma.
2. A pleural effusion after CAR‑T is not automatically “localized CRS.” It may represent infection, heart failure, bleeding, lymphatic obstruction, disease progression, pulmonary embolism, or systemic capillary leak. New or worsening fluid requires clinical assessment and imaging.
3. There is no general rule that all pre-infusion effusions should be drained until the pleural space is “as dry as possible.” Drainage should be symptom-, ultrasound- and respiratory-status guided. In a multiseptated effusion, a pigtail may not drain all compartments, and repeated procedures carry bleeding, infection, lung-injury and re-expansion risks.
4. Tocilizumab and corticosteroids must not be given pre-emptively for a presumed pleural CRS. They are decisions for the CAR‑T treating team after assessing the recognised CRS/ICANS grading and alternative causes.
*THE KEY DECISION*
Before investing in CAR‑T, the treating haematology team should confirm:
▪️ The exact disease entity: CLL/SLL, transformed diffuse large B-cell lymphoma, another mature B-cell lymphoma, or a mixed process.
▪️ Concordance of *CD19, CD20, CD5, CD23, CD10, FMC7, CD200 and light-chain expression* between pleural fluid, prior lymph-node tissue and blood.
▪️ Whether there is adequate viable CD19-positive disease for the proposed trial/product.
▪️ Echocardiographic, renal, hepatic, marrow and functional-status eligibility.
▪️ Expected benefit versus treatment-related mortality, prolonged hospitalisation, CRS, neurotoxicity, infection and cytopenias.
▪️ Whether the trial accepts an 86-year-old with recurrent effusion, frailty, anaemia, renal impairment and prior oxygen/NIV requirement.
For this patient, the question is not simply *“Can CAR‑T reach the pleura?”* It is:
*“Is there a sufficiently defined CD19-positive disease target, and is the anticipated chance of meaningful respiratory and survival benefit greater than the substantial toxicity and logistical burden?”*
A trial review by the CAR‑T haematology team is reasonable if the patient and advocate understand that this is *high-risk, protocol-dependent treatment*, not an established pleural-effusion treatment. The recurrent effusion should be managed in parallel for symptom relief; it should not be assumed that CAR‑T will promptly resolve it. The new observations and the CAR‑T deliberation are recorded in the active case context*Short case 1801006116*:
https://navyathapothularollno110.blogspot.com/2023/03/this-is-online-e-log-book-to-discuss.html
.
[03/10, 08:52]hu2: Thanks for that appropriate socratic steelman counter 👏
[03/10, 08:53] PaJR Health Bot Feb 26: Agreed. The counter keeps the important distinction between:
▪️ *Biological plausibility* — CD19-positive pleural disease may be targetable.
▪️ *Clinical evidence* — reliable benefit in this specific frail 86-year-old remains unproven.
▪️ *Treatment feasibility* — eligibility, organ reserve, toxicity risk and trial criteria may be decisive.
▪️ *Causal uncertainty* — pleural fluid may be simultaneously malignant, cardiac, lymphatic or treatment-related.
The safest framing remains: *CAR‑T trial evaluation may be reasonable, but only after formal product-specific eligibility review and an explicit benefit–harm discussion. It should not be presented as established treatment for the recurrent pleural effusion.*
No comments:
Post a Comment